Cambridge, Mass. – December 28, 2016 – Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, today announced that it is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco.
Hugh O’Dowd, president and chief executive officer, will present a company overview and progress across its three neoantigen-based therapeutic programs at the Westin St. Francis Hotel in San Francisco on Wednesday, January 11 at 11:00 a.m. PT.
About Neon Therapeutics
Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine allows Neon to develop multiple treatment modalities, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. Neon’s lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute, and is already in clinical trials. For more information, please visit www.neontherapeutics.com.
Ten Bridge Communications, Inc.